TAP HERE TO SEE THE PRODUCT

Transcription

1 TAP HERE TO SEE THE PRODUCT

2 Make every testing opportunity count. Acute infection accounts for 5-20% of all cases of HIV infection among persons seeking testing.1 This acute phase of infection is associated with peak levels of viremia and high risk of transmission. By quickly and accurately identifying HIV positive patients earlier, this will increase case finding and facilitate fast and appropriate linkage to care.

3 A new standard in HIV screening AlereTM HIV Combo is an in vitro, visually read, qualitative lateral flow immunoassay for the simultaneous detection of free non immunocomplexed HIV-1 p24 antigen (Ag) and antibodies (Ab) to HIV-1 and HIV-2 in human blood. The test specimen can be serum, plasma, fingerstick or venous whole blood. It detects more acute infections compared to 2 nd and 3 rd generation tests which helps close the window period and enables increased case finding at a time when individuals are highly infectious. Days Months Years Additional Window HIV-1 p24 antigen HIV-1/2 antibodies High viral load & infection risk 3 rd Generation Rapid Test HIV-1/2 Antibody only tests 4 th Generation Rapid Test Alere TM HIV Combo: HIV-1 p24 Anigen + HIV-1/2 Antibodies on a single POC test strip* Days of infection *Not comparable to molecular testing

4 A pathway to improved prognosis with 4 th generation point-of-care testing Improved access More individuals are empowered to know their status through point of care testing. Earlier detection Leading to increased case finding of highly infectious individuals. Rapid, accurate screening Helps close the window period and provides confidence in results at the point of care. Immediate counselling Reducing patient loss to follow up and allowing immediate partner notification. Improved prognosis Detecting HIV earlier leads to better patient outcomes. Timely patient management Ability to commence appropriate treatment sooner. Faster assessment and staging Providing fast linkage to care and decreasing risk of onward transmission.

5 Distribution of HIV-Subtypes in the African Region 2 B CRF02_AG, other recombinants F, G, H, J, K, CRF01 other recombinants A, B, AB recombinant B, C, BC recombinant A C D Insufficient Data HIV-1 antigens HIV-1 group M subtype A, B, C, D, F, G, H and CRF01-AE, CRF02-AG, and HIV-1 group O are all detectable with AlereTM HIV Combo. 3 HIV antibodies HIV-1 group M subtype A, B, C, D, F, G, H, J, K, CRF01-AE, CRF02-AG, CRF03-AB CRF05-DF, CRF09-A/U, CRF11-cpx, HIV-1 group O and HIV-2 are all detectable with AlereTM HIV Combo. 3

6 Performance Sensitivity* 100% Product Information Method Lateral flow Specificity 99.72% Time to results 20 minutes Storage conditions 2-30 C Sample volume 50µl *Please refer to the Product Insert for the analytical sensitivity of HIV-1 p24 Antigen. Test shelf life Sample types 18 months Serum/plasma, fingerstick whole blood and venipuncture whole blood New possibilities in patient care By closing the window period AlereTM HIV Combo sets a new standard in point of care testing. This simple test delivers fast, accurate results in 20 minutes introducing new possibilities in patient care. Order info Product AlereTM HIV Combo 20 test kit AlereTM HIV Combo 100 test kit Chase Buffer EDTA Capillary Tubes Catalogue Number 7D2842 7D2843 7D2243 7D2222 References 1. Branson, B and Stekler, J. D, Detection of Acute HIV Infection; We can't close the window, Journal of Infectious Disease, 2012, 205: Francine E. McCutchan, Henry M. Jackson Foundation (Rockville, Maryland). IAVI Report, August 2003 [online] available at 3. Alere HIV Combo Product Insert. Data on file. For more information, contact your local Alere representative or visit alerehiv.com 2016 Alere. All rights reserved. The Alere Logo, Alere and Knowing now matters are trademarks of the Alere group of companies. Photos are used for illustrative purposes only. Any person depicted in the photos is a model E-05 02/16 TAP HERE TO RETURN TO THE COVER